FEATURED NEWS
NEWS: MOSAIC PROTEIN NANOPARTICLES ELICIT BROADLY CROSS-REACTIVE ANTI-SARS AND SARS-RELATED VIRUS RESPONSES IN PREVIOUSLY VACCINATED ANIMALS (AUG 2024)
Congratulations to Paulo Lin, co-author of a recent study featured in Cell. He collaborated with scientists from the Division of Biology and Biological Engineering, California Institute of Technology on research to develop a protein nanoparticle-based vaccine with eight different SARS-like virus receptor binding domains that provides broad protection against new SARS-2 variants as well as unknown SARS-related viruses in previously vaccinated animals. Click to read more info.
NEWS: COMPARISON OF URIDINE AND N1-METHYLPSEUDOURIDINE mRNA PLATFORMS IN DEVELOPMENT OF AN ANDES VIRUS VACCINE (JUL 2024)
Congratulations to Jennifer Moon, co-author of a recent study featured in Nature Communications. She collaborated with scientists from the Departments of Microbiology and Immunology, Biochemistry and Molecular Biology, and Pathology at the University of Texas Medical Branch to study mRNA vaccines against the Andes virus. Click to read more info.
NEWS: THE ROLES OF CD4+ T CELL HELP, SEX, AND DOSE IN THE INDUCTION OF PROTECTIVE CD8+ T CELLS AGAINST A LETHAL POXVIRUS BY mRNA-LNP VACCINES (JUL 2024)
Congratulations to Ying Tam, co-author of a recent study featured in Molecular Therapy. He collaborated with scientists from Thomas Jefferson University and the Pardi Lab at the University of Pennsylvania Perelman School of Medicine, studying the role of CD4+ T cell help in CD8+ T cell responses to an mRNA-LNP vaccine’s effectiveness and design. Click to read more info.